Conclusions
There was no difference in the magnitude of decrease of the AVNBCL and
VABCL relative to the magnitude in decrease of the SCL at each
incremental dose of dobutamine. However, the AVNBCL, the VABCL and the
SCL decreased significantly from baseline with each incremental dose of
dobutamine (except the 3% decrease in SCL from baseline to 5 mcg/kg/min
dobutamine was not statistically significant). Dobutamine was also seen
to enhance retrograde AV nodal conduction in two out of three patients
who displayed no retrograde conduction at baseline. While hypotension
and arrhythmia-inductions were noted, no significant hypertensive nor
further adverse events were noted, which deems dobutamine a safe
alternative to isoproterenol for EPS.
Other Members of the Dobutamine Study Group:
Aushim Kokroo, M.D.1, Parmanand Dasrat,
M.D.1, Ali
Seyar Rahyab1, M.D.1